Cancer jab can eradicate entire tumours in patients, trial shows
A new cancer treatment trial has shown promising results, with a jab called amivantamab able to eradicate tumors in some patients. The trial involved 102 patients with head and neck cancer, and over a third experienced significant tumor shrinkage. This treatment could potentially benefit many patients who have limited options due to resistance to traditional therapies.
- ▪The amivantamab jab shrank tumors in more than a third of patients in the trial.
- ▪Fifteen patients had their tumors completely eradicated after treatment.
- ▪The jab is administered under the skin, making it more convenient than traditional intravenous treatments.
2 outlets in our directory ran this story, first to last over 1 hour. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
The Guardian — World publishes from United Kingdom and files mainly under world. We currently carry 3,174 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Guardian — World |
| Canonical URL | https://www.theguardian.com/science/2026/may/30/cancer-jab-can-eradicate-entire-tumours-in-patients-trial-shows |
| Publication time | Sat, 30 May 2026 17:00:24 GMT |
| Retrieval time | 2026-05-30T17:09:42.852Z |
| Last seen | 2026-05-30T17:09:42.852Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | qtqjtX2RJrem · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024, joined the OrigAMI-4 trial at the Royal Marsden in July 2025. Photograph: HandoutView image in fullscreenCarl Walsh, 56, who was diagnosed with tongue cancer in May 2024, joined the OrigAMI-4 trial at the Royal Marsden in July 2025. Photograph: HandoutCancer researchCancer jab can eradicate entire tumours in patients, trial showsJab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapyAndrew Gregory Health editor, in ChicagoSat 30 May 2026 13.00 EDTLast modified on Sat 30 May 2026 13.01 EDTSharePrefer the Guardian on GoogleDoctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumours in patients.In an…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — World.
Discussion
0 commentsMore from The Guardian — World
